Correspondence 0001654954-22-015659 from Dermata Therapeutics, Inc. (DRMA)
Dermata Therapeutics, Inc.
Date: Nov. 22, 2022 · CIK: 0001853816 · Accession: 0001654954-22-015659
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-268383
Letter
drma-accelerationrequestf
Dermata Therapeutics, Inc.
3525 Del Mar Heights, Road, #322
San Diego, CA 92130
Tel: (858) 800-2543
November 22, 2022
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
Dermata Therapeutics, Inc.
Registration Statement on Form S-3 (File No. 333-268383)
Filed on November 15, 2022
Ladies and Gentlemen:
Dermata Therapeutics, Inc. (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on November 25, 2022, at 5:00 p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant, or its representative, may orally request via telephone call to the staff of the Commission.
Please call Steven M. Skolnick of Lowenstein Sandler LLP at (646) 414-6947 to confirm the effectiveness of the Registration Statement or with any questions.
Very
truly yours,
DERAMTA
THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm drma-accelerationrequestf Dermata Therapeutics, Inc. 3525 Del Mar Heights, Road, #322 San Diego, CA 92130 Tel: (858) 800-2543 November 22, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Dermata Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-268383) Filed on November 15, 2022 Ladies and Gentlemen: Dermata Therapeutics, Inc. (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on November 25, 2022, at 5:00 p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant, or its representative, may orally request via telephone call to the staff of the Commission. Please call Steven M. Skolnick of Lowenstein Sandler LLP at (646) 414-6947 to confirm the effectiveness of the Registration Statement or with any questions. Very truly yours, DERAMTA THERAPEUTICS, INC. By: /s/ Gerald T. Proehl Name: Gerald T. Proehl Title: Chief Executive Officer